Objective Through assessing the quality of systematic reviews/meta-analyses conducted by hospital pharmacists in China, to learn relevant situations and to promote the development and application of evidence-based pharmacy in hospital. Methods The following databases such as CBM, CNKI, Wanfang Database, VIP, CMCI, The Cochrane Library, EMbase and PubMed were searched from the establishment date to April 15th, 2011, to collect all published systematic reviews/meta-analyses conducted by hospital pharmacists in China. Two reviewers independently extracted the published information according to the inclusive and exclusive criteria, and assessed the methodology and reporting quality of the included literatures with OQAQ and PRISMA. Disagreements were discussed or resolved by the third reviewer. Data analysis was conducted by using SPSS17.0 software. Results Two hundred and sixteen Chinese literatures (including 40 on traditional Chinese medicine), and 15 English literatures were identified. The number of literatures has increased rapidly since 2008. Beijing and Sichuan were the top 2 districts in the number of literatures. All of the included literatures were published in 62 magazines sponsored by 87 hospitals, such as China Pharmacy, and Chinese Journey of Evidence-Based Medicine. The total downloads of Chinese literatures were 14346, and the total citations of all literatures were 154. The methodology and reporting quality of the randomized controlled trials (RCTs) involved in 220 systematic reviews/meta-analyses literatures were assessed, which showed the highest and lowest scores of methodological quality were 6 and 3, respectively, and the average score was 4.27±0.55. The highest and lowest scores of reporting quality were 22.5 and 9, respectively, and the average score was 16.49±2.98. Conclusion Although the evidence-based pharmacy in hospital begins late in China, it develops rapidly, and offers lots of evidence to policy decision, guidelines and rational drug use. However, there is still room for improvement of the methodology and reporting quality in future reviews.
ObjectiveTo investigate the reporting and methodological quality of systematic reviews/ meta-analyses conducted by hospital pharmacists in China, so as to improve the quality of systematic reviews/ meta-analyses in this field. MethodsThe literatures were retrieved from CNKI, WanFang Data, VIP, CBM, CMCI, PubMed, EMbase, The Cochrane Library from the establishment date to March 17th, 2016. According to the inclusive and exclusive criteria, authors independently screened and extracted the published information. Reporting and methodological quality of included reviews were evaluated by PRIMSA statements and AMSTAR checklists. Data analysis was conducted by using Excel 2013 software and SPSS 20.0 software. ResultsOne thousand and eighteen systematic reviews/ meta-analyses were included, including 871 Chinese literatures and 147 English literatures. The average score of PRIMSA was 18.41±2.84, and the average score of AMSTAR was 7.38±1.28. The main problems of PRIMSA were structured summary, objectives, protocol and registration, additional analyses and funding. The main problems of AMSTAR were priori design, status of publication and list of studies (included and excluded). Univariate analysis showed that some factors could improve the quality of methodology and reporting, including studies in English (P<0.000 1), published after checklists' (P<0.000 1), hospital in higher-level (P<0.000 1), illuminating the funding or interest conflict (P<0.000 1). Pearson analysis indicated that linear correlation were detected between PRISMA scores and AMSTAR scores (P<0.000 1), as well as citations and AMSTAR scores (P=0.045). ConclusionEvidenced-based pharmacy in hospital has developed rapidly, the quality of methodology and reporting have increaseed year by year, but further improvement should be considered in different aspects. The methods to evaluate the clinical application of these systematic reviews/ meta-analyses should be developed in the future.
Objective To investigate the current status of systematic reviews/meta-analyses published by pharmacists in hospital in China by using bibliometric analysis and assessing the methodological quality of these studies. Methods The literatures were searched from CNKI, WanFang Data, VIP, CBM, CMCI, PubMed, EMbase, The Cochrane Library (Issue 2, 2016) from the establishment to March 17th, 2016. According to the inclusive and exclusive criteria, the authors independently screened literature and extracted the data. Methodology quality and reporting quality were evaluated by using AMSTAR tool and PRIMSA statement. Data analysis was conducted by using Excel 2013 and SPSS 20.0 software. Results A total of 1 018 systematic reviews/meta-analyses were included of which 871 were published in Chinese and 147 were in English. The published literature increased year by year, as well as the reporting quality and methodological quality. All of the included studies were published in 146 Chinese journals and 97 English journals. The authors were from 308 hospitals of 27 provinces. Drug effectiveness and drug safety were mainly assessed, and western medicine was the main category. Most of these studies were focused on anti-tummor drugs. Conclusion Evidenced-based drug evaluation by hospital pharmacists in China is rapidly increasing as well as the methodological quality and reporting quality, however, the development is unbalanced in China, and evidence-based medicine should be further promoted in the field of hospital pharmacy.
As an important source for real-world data, existing health and medical data have gained wide attentions recently. As the first part of the serial technical guidance for real-world data and studies, this report introduced the concepts, features and potential applications of existing medical and health data, proposed recommendations for planning and developing a research database using existing health and medical data, and developed essential indicators for assessing the quality of such research databases. The technical guidance may standardize and improve the development of research database using existing health and medical data in China.